Paracoccidioidomycosis (PCM), initially reported in 1908 in the city of São Paulo, Brazil, by
Adolpho Lutz, is primarily a systemic and neglected tropical mycosis that may affect …

Antibodies are highly functional glycoproteins capable of providing immune protection
through multiple mechanisms, including direct pathogen neutralization and the engagement …

The increasing incidence in systemic fungal infections in humans has increased focus for
the development of fungal vaccines and use of monoclonal antibodies. Invasive mycoses …

Vaccination is one of the greatest public health achievements in the past century, protecting
and improving the quality of life of the population worldwide. However, a safe and effective …

Paracoccidioidomycosis (PCM) is the most relevant systemic endemic mycosis limited to
Latin American countries. The etiological agents are thermally dimorphic species of the …

Protective immunity against Paracoccidioides consists of a stepwise activation of numerous
effector mechanisms that comprise many cellular and soluble components. At the initial …

Introduction Fungal infections are caused by a broad range of pathogenic fungi that are
found worldwide with different geographic distributions, incidences, and mortality rates …

Paracoccidioidomycosis (PCM) is a systemic mycosis with lymphatic dissemination that is
caused by Paracoccidioides species. Treatment of PCM consists of chemotherapeutics such …

The genus Paracoccidioides consist of dimorphic fungi geographically limited to the
subtropical regions of Latin America, which are responsible for causing deep systemic …

Monoclonal antibodies (mAbs) are promising alternatives to treat infectious diseases,
especially given their potential for applications in combination therapies with antimicrobial …